Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gallbladder01:17

Gallbladder

2.8K
The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins...
2.8K
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

3.2K
Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
3.2K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

16.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.7K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.6K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

3.8K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective epidemiological study in an Aotearoa New Zealand cohort.

The New Zealand medical journal·2026
Same author

A Return to Normality: A Descriptive Qualitative Interview Study Exploring the Patient Experience of Gout Flare Resolution.

Arthritis care & research·2026
Same author

Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system.

Annals of the rheumatic diseases·2026
Same author

Mitonuclear Discordance and Gout, Type 2 Diabetes and Chronic Kidney Disease in Aotearoa New Zealand Indigenous Māori and Pacific People.

Annals of human genetics·2026
Same author

Revisiting the Ethics of Urate-Lowering Therapy Clinical Trials for Gout Management.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Misclassified latent autoimmune diabetes in adults within Māori and Pacific adults with type 2 diabetes in Aotearoa New Zealand.

The New Zealand medical journal·2025
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 22, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

Gout.

Nicola Dalbeth1, Tony R Merriman2, Lisa K Stamp3

  • 1Department of Medicine, University of Auckland, Auckland, New Zealand.

Lancet (London, England)
|April 27, 2016
PubMed
Summary
This summary is machine-generated.

Effective gout management requires lowering serum urate levels to below 360 μmol/L. Despite available treatments like allopurinol, low initiation and continuation rates of urate-lowering therapy hinder flare suppression.

More Related Videos

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.6K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Related Experiment Videos

Last Updated: Mar 22, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.6K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Area of Science:

  • Rheumatology
  • Crystal-induced arthritis
  • Immunology

Background:

  • Gout is a chronic condition caused by monosodium urate crystal deposition due to elevated serum urate.
  • Genetic and environmental factors influence hyperuricemia, with renal and gut urate excretion being key regulatory mechanisms.
  • NLRP3 inflammasome activation and interleukin-1β release are crucial in initiating acute gout flares.

Purpose of the Study:

  • To emphasize the importance of a "treat to target serum urate" strategy for effective gout management.
  • To highlight the goal of long-term serum urate reduction to <360 μmol/L for crystal dissolution and flare suppression.
  • To identify the need for improved strategies in gout care quality.

Main Methods:

  • Review of current understanding of gout pathophysiology, including crystal formation and inflammatory pathways.
  • Discussion of therapeutic approaches, including allopurinol dose escalation and newer urate-lowering drugs.
  • Analysis of global trends in urate-lowering therapy initiation and continuation rates.

Main Results:

  • Achieving serum urate targets (<360 μmol/L) is essential for gout management, leading to crystal dissolution and flare suppression.
  • Allopurinol dose escalation is often effective, and new urate-lowering medications are available.
  • Worldwide, urate-lowering therapy initiation and adherence are suboptimal, resulting in infrequent achievement of treatment targets.

Conclusions:

  • A "treat to target serum urate" approach is fundamental for managing gout effectively.
  • Current low rates of urate-lowering therapy utilization impede successful gout management globally.
  • There is a critical need for enhanced strategies to improve the quality of gout care and patient adherence to treatment.